|Bid||115.52 x 100|
|Ask||127.00 x 200|
|Day's Range||121.83 - 124.53|
|52 Week Range||77.58 - 153.15|
|PE Ratio (TTM)||-219.63|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.